CIP
ADMA icon

Chartwell Investment Partners’s ADMA Biologics ADMA Stock Holding History

Chartwell Investment Partners’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$4.99M Buy
249,779
+2,038
+0.8% +$31.7K 0.17% 185
2024
Q2 		$2.77M Buy
247,741
+83,803
+51% +$703K 0.1% 243
2024
Q1 		$1.08M Buy
+163,938
New +$896K 0.04% 362

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Chartwell Investment Partners's ADMA Position: Q3 2024 in Review

Chartwell Investment Partners increased its ADMA Biologics (ADMA) stake by 0.82% in Q3 2024, buying an estimated $31.7K and bringing the position to 249,779 shares worth $4.99M. The position accounts for 0.17% of the portfolio, ranked #185.

Chartwell Investment Partners first reported a position in ADMA in Q1 2024 and has held it in 3 quarters since. 306 funds tracked by Wall St. Rank hold ADMA as of Q3 2024.

  • Chartwell Investment Partners held 249,779 shares of ADMA Biologics worth $4.99M as of Q3 2024.
  • Chartwell Investment Partners bought 2,038 ADMA Biologics shares in Q3 2024, an estimated $31.7K.
  • ADMA Biologics made up 0.17% of Chartwell Investment Partners's portfolio in Q3 2024, its #185 holding.
  • Chartwell Investment Partners first reported a position in ADMA Biologics in Q1 2024 and has held it in 3 quarters since.
  • 306 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2024.

Based on Chartwell Investment Partners's 13F filing for Q3 2024, filed 4 Nov 2024.